Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Jul 8;5(7):e148.
doi: 10.1371/journal.pmed.0050148.

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared

Olivia Keiser  1 , Catherine Orrell, Matthias Egger, Robin Wood, Martin W G Brinkhof, Hansjakob Furrer, Gilles van Cutsem, Bruno Ledergerber, Andrew Boulle; Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA)
Collaborators, Affiliations
Comparative Study

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared

Olivia Keiser et al. PLoS Med. .

Erratum in

  • PLoS Med. 2008 Sep;5(9):e195

Abstract

Background: The provision of highly active antiretroviral therapy (HAART) in resource-limited settings follows a public health approach, which is characterised by a limited number of regimens and the standardisation of clinical and laboratory monitoring. In industrialized countries doctors prescribe from the full range of available antiretroviral drugs, supported by resistance testing and frequent laboratory monitoring. We compared virologic response, changes to first-line regimens, and mortality in HIV-infected patients starting HAART in South Africa and Switzerland.

Methods and findings: We analysed data from the Swiss HIV Cohort Study and two HAART programmes in townships of Cape Town, South Africa. We included treatment-naïve patients aged 16 y or older who had started treatment with at least three drugs since 2001, and excluded intravenous drug users. Data from a total of 2,348 patients from South Africa and 1,016 patients from the Swiss HIV Cohort Study were analysed. Median baseline CD4+ T cell counts were 80 cells/mul in South Africa and 204 cells/mul in Switzerland. In South Africa, patients started with one of four first-line regimens, which was subsequently changed in 514 patients (22%). In Switzerland, 36 first-line regimens were used initially, and these were changed in 539 patients (53%). In most patients HIV-1 RNA was suppressed to 500 copies/ml or less within one year: 96% (95% confidence interval [CI] 95%-97%) in South Africa and 96% (94%-97%) in Switzerland, and 26% (22%-29%) and 27% (24%-31%), respectively, developed viral rebound within two years. Mortality was higher in South Africa than in Switzerland during the first months of HAART: adjusted hazard ratios were 5.90 (95% CI 1.81-19.2) during months 1-3 and 1.77 (0.90-3.50) during months 4-24.

Conclusions: Compared to the highly individualised approach in Switzerland, programmatic HAART in South Africa resulted in similar virologic outcomes, with relatively few changes to initial regimens. Further innovation and resources are required in South Africa to both achieve more timely access to HAART and improve the prognosis of patients who start HAART with advanced disease.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: HF has participated in advisory boards of GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS), Gilead, Merck Sharp & Dohme-Chibret (MSD) and Boehringer-Ingelheim. The institution of HF has received unrestricted educational grants from Abbott, GSK, BMS, Roche, Gilead, MSD, Boehringer-Ingelheim, and Essex. The other authors declare that they have no competing interests.

Figures

Figure 1
Figure 1. Rates and Kaplan-Meier Plots of First Treatment Change Due to Toxicity, Failure, and Other Reasons in Khayelitsha and Gugulethu, South Africa and the Swiss HIV Cohort Study
Dots indicate rates during months 1–3, 4–6, 7–12, and 13–24 with 95% CIs; lines indicate the estimated proportion of patients changing their first-line regimen. “Other reasons” (bottom graph) include mainly treatment changes due to tuberculosis and pregnancy in South Africa and changes due to patients' wishes or physicians' decisions in Switzerland.
Figure 2
Figure 2. Frequency of Viral Load Measurements in Khayelitsha and Gugulethu, South Africa and the Swiss HIV Cohort Study
The frequency was standardized to the total number of measurements in each setting.
Figure 3
Figure 3. Kaplan Meier Plots of Virologic Response, Viral Rebound, and Mortality in Khayelitsha and Gugulethu, South Africa and the Swiss HIV Cohort Study
Viral rebound is defined as having a HIV-1 RNA >500 copies/ml after a viral load ≤500 copies/ml.
See this image and copyright information in PMC

References

    1. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ. 1997;315:1194–1199. - PMC - PubMed
    1. World Health Organization. Recommendations for a public health approach. Geneva: WHO; 2006. Antiretroviral therapy for HIV Infection in adults and adolescents in resource-limited settings: towards universal access. Available at: http://www.who.int/hiv/pub/guidelines/WHO%20Adult%20ART%20Guidelines.pdf. Accessed 5 June 2008.
    1. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;368:505–510. - PubMed
    1. Beck EJ, Vitoria M, Mandalia S, Crowley S, Gilks CF, et al. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines. AIDS. 2006;20:1497–1502. - PubMed
    1. World Health Organisation, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress Report, April 2007. Geneva: WHO; 2007. Available at: http://libdoc.who.int/publications/2007/9789241595391_eng.pdf. Accessed 5 June 2008.

Publication types